Sanford Svai S
Known title: Chief Financial OfficerCIK: 0001591411
Associated companies
Transaction History
| RANI | ▲ Buy | Grant | 139,000 | $0 | 3/27/2023 | View on chart |
| RANI | ▼ Sell | Tax Withholding | 3,355 | $20K | 3/22/2023 | View on chart |
| RANI | ▼ Sell | Tax Withholding | 18,362 | $182K | 9/9/2022 | View on chart |
| RANI | ▲ Buy | Grant | 32,900 | $0 | 3/22/2022 | View on chart |
| RANI | ▲ Buy | Grant | 106,200 | $0 | 9/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RANI joins FDA Emerging Technology Platform
Rani Therapeutics was added to the FDA’s Emerging Technology Platform, a program that highlights innovative medical technologies. The inclusion signals that the FDA sees potential in the company’s approach and may facilitate future regulatory interactions. This development comes as the stock is trading near its recent support level.
RANI joins FDA Emerging Technology Platform. Rani Therapeutics was added to the FDA’s Emerging Technology Platform, a program that highlights innovative medical technologies. The inclusion signals that the FDA sees potential in the company’s approach and may facilitate future regulatory interactions. This development comes as the stock is trading near its recent support level.